Waldheim Pharmazeutika's (Austria) HIV-2 confirmatory well on its way through FDA
This article was originally published in Clinica
Waldheim Pharmazeutika (Austria) says the US FDA has accepted Product and Establishment Licence Applications for its HIV-2 confirmatory immunofluorescence assay, Fluorognost HIV-2 IFA. "In spite of its huge review burden, the FDA Center of Biologics has sent the filing letter very quickly, and without requesting any further information at this point," said Dr Hermann Mucke, managing director of Waldheim's Diagnostics Division. "We believe that the Agency wants an approved HIV-2 confirmatory test out on the US market as soon as possible."
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.